LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer

被引：0
|
作者：
Xi Jin
Li-Ping Ge
Da-Qiang Li
Zhi-Ming Shao
Gen-Hong Di
Xiao-En Xu
Yi-Zhou Jiang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Breast Surgery
[2] Fudan University Shanghai Cancer Center,Cancer Institute
[3] Fudan University,Department of Oncology, Shanghai Medical College
[4] Fudan University Shanghai Cancer Center,Precision Cancer Medicine Center
[5] Key Laboratory of Breast Cancer in Shanghai,undefined
来源：
Molecular Cancer | / 19卷
关键词：
Breast cancer; lncRNA TROJAN; CDK4/6 inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Cdk4/6 kinase inhibitor resistance in prostate cancer
    De Leeuw, Renee
    Schiewer, Matthew J.
    McNair, Christopher
    Augello, Michael A.
    Yoshida, Akihiro
    Hazard, Edward S.
    Courtney, Sean
    Hardiman, Gerard T.
    Drake, Justin
    Feng, Felix Y.
    Tomlins, Scott
    Hussain, Maha H.
    Diehl, J. Alan
    Kelly, William K.
    Knudsen, Karen E.
    CANCER RESEARCH, 2017, 77
  • [42] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [43] TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
    Li, Meihua
    Niu, Chengshan
    Chen, Mingtao
    Ji, Kaige
    Xu, Hui
    Dong, Shengli
    Zhang, Yan
    Meng, Qinguo
    Dou, Yuge
    Wang, Yijun
    Wu, Rui
    Tu, Yian
    Zhou, Chao
    Liang, Apeng
    Wang, Huan
    Ni, Rongzhen
    Gong, Aishen
    Su, Hui
    Jiang, Mingyu
    Xing, Feng
    Chen, Shaoqing
    Chen, Xiugui
    Li, Jun
    Wu, Yusheng
    CANCER RESEARCH, 2023, 83 (07)
  • [44] The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations
    Soria-Bretones, Isabel
    Thu, Kelsie L.
    Silvester, Jennifer
    Cruickshank, Jennifer
    El Ghamrasni, Samah
    Ba-alawi, Wail
    Fletcher, Graham C.
    Kiarash, Reza
    Elliott, Mitchell J.
    Chalmers, Jordan J.
    Elia, Andrea C.
    Cheng, Albert
    Rose, April A. N.
    Bray, Mark R.
    Haibe-Kains, Benjamin
    Mak, Tak W.
    Cescon, David W.
    SCIENCE ADVANCES, 2022, 8 (36)
  • [45] Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
    Main, Sasha C.
    Cescon, David W.
    Bratman, Scott, V
    CANCER DRUG RESISTANCE, 2022, 5 (03) : 727 - 748
  • [46] Proteogenomic characterization of CDK4/6 inhibitor-resistant ER plus breast cancer
    Chen, Christopher T.
    Leshchiner, Ignaty
    Martin, Liz
    Kane, Harry
    Rhrissorrakrai, Kahn
    Utro, Filippo
    Levovitz, Chaya
    Gillette, Michael
    Satpathy, Shankha
    Pinto, Christopher
    McLoughlin, Daniel
    Allen, Read
    Danysh, Brian P.
    Slowik, Kara
    Jacobs, Raquel A.
    Carr, Steven
    Parida, Laxmi
    Getz, Gad
    Juric, Dejan
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [47] High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Palafox, Marta
    Monserrat, Laia
    Bellet, Meritxell
    Villacampa, Guillermo
    Gonzalez-Perez, Abel
    Oliveira, Mafalda
    Braso-Maristany, Fara
    Ibrahimi, Nusaibah
    Kannan, Srinivasaraghavan
    Mina, Leonardo
    Herrera-Abreu, Maria Teresa
    Odena, Andreu
    Sanchez-Guixe, Monica
    Capelan, Marta
    Azaro, Analia
    Bruna, Alejandra
    Rodriguez, Olga
    Guzman, Marta
    Grueso, Judit
    Viaplana, Cristina
    Hernandez, Javier
    Su, Faye
    Lin, Kui
    Clarke, Robert B.
    Caldas, Carlos
    Arribas, Joaquin
    Michiels, Stefan
    Garcia-Sanz, Alicia
    Turner, Nicholas C.
    Prat, Aleix
    Nuciforo, Paolo
    Dienstmann, Rodrigo
    Verma, Chandra S.
    Lopez-Bigas, Nuria
    Scaltriti, Maurizio
    Arnedos, Monica
    Saura, Cristina
    Serra, Violeta
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [48] High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Marta Palafox
    Laia Monserrat
    Meritxell Bellet
    Guillermo Villacampa
    Abel Gonzalez-Perez
    Mafalda Oliveira
    Fara Brasó-Maristany
    Nusaibah Ibrahimi
    Srinivasaraghavan Kannan
    Leonardo Mina
    Maria Teresa Herrera-Abreu
    Andreu Òdena
    Mònica Sánchez-Guixé
    Marta Capelán
    Analía Azaro
    Alejandra Bruna
    Olga Rodríguez
    Marta Guzmán
    Judit Grueso
    Cristina Viaplana
    Javier Hernández
    Faye Su
    Kui Lin
    Robert B. Clarke
    Carlos Caldas
    Joaquín Arribas
    Stefan Michiels
    Alicia García-Sanz
    Nicholas C. Turner
    Aleix Prat
    Paolo Nuciforo
    Rodrigo Dienstmann
    Chandra S. Verma
    Nuria Lopez-Bigas
    Maurizio Scaltriti
    Monica Arnedos
    Cristina Saura
    Violeta Serra
    Nature Communications, 13
  • [49] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [50] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
12345